Login to Your Account



Regeneron Seeks FDA Approval of VEGF Trap-Eye for Wet AMD

By Marie Powers


Wednesday, February 23, 2011
As expected, Regeneron Pharmaceuticals Inc. submitted a biologics license application (BLA) to the FDA for its VEGF Trap-Eye (aflibercept ophthalmic solution) to treat the neovascular form of age-related macular degeneration (wet AMD). Regeneron's submission includes a request for priority PDUFA review.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription